BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Interim Report for the period July – September 2025

Thu, Nov 13, 2025 08:00 CET

Broadening our portfolio with new projects and partnershipsEvents during the third quarter 2025 · New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and safety, real world evidence and subcutaneous dosing · Option, collaboration and license agreement signed with Novartis, with an upfront payment of USD 30 M. The agreement is for a potential treatment combining BioArctic's BrainTransporter technology with a Novartis proprietary antibody · US FDA approved weekly subcutaneous maintenance treatment with Leqembi® Iqlik™ for the treatment of early

There are no items matching the current filter

There are no more items matching the current filter

About Us

Interim Report for the period July – September 2025

Subscribe

Media

Share

About Us

Interim Report for the period July – September 2025

Subscribe

Media